Blood Health

AspirinWorks® (11-dehydro thromboxane B2/Creatinine, or 11-dhTXB2/Creatinine) is a unique biomarker used to evaluate the effectiveness of aspirin in inhibiting thromboxane production, which is crucial for platelet function and clot formation. This biomarker specifically measures the levels of 11-dehydro thromboxane B2 (11-dhTXB2) in the urine, which is a stable metabolic product of thromboxane A2, the molecule that aspirin targets to reduce platelet aggregation. By normalizing this measurement to creatinine, a byproduct of muscle metabolism consistently present in urine, the test provides a reliable assessment of thromboxane production on a per kidney filtration rate basis. The AspirinWorks® test is particularly useful for determining if patients on low-dose aspirin therapy are receiving the appropriate antiplatelet effect to prevent conditions like heart attacks and strokes. This test is crucial for identifying aspirin resistance, a condition where individuals do not respond to the standard antiplatelet effects of aspirin, thus allowing for adjustments in their therapeutic regimen. Understanding the level of 11-dhTXB2 can help healthcare providers make more informed decisions regarding aspirin dosing, potentially leading to better cardiovascular outcomes for patients at risk of thrombotic events.

Absolute Reticulocyte Count (ARC) is a critical blood test used to assess the bone marrow's ability to produce red blood cells (RBCs), essential for diagnosing and managing various hematological conditions. Reticulocytes are immature red blood cells, and their absolute count indicates the rate of RBC production. This test is particularly vital for patients with anemia or those undergoing treatments like chemotherapy, as it helps determine whether the bone marrow is responding adequately. A high Absolute Reticulocyte Count can suggest excessive RBC destruction or loss, as seen in conditions like hemolytic anemia, while a low count may indicate inadequate RBC production, common in bone marrow failure. The ARC test is a key diagnostic tool in understanding and managing blood disorders, guiding treatment decisions, and monitoring the effectiveness of therapies. Its significance in medical diagnostics underscores its role in advancing patient care and treatment strategies.

Clot-regulating enzyme

two alleles that make up your Alpha-1 gene

a protein that is made in the liver. It helps protect your lungs from damage and diseases.

Ammonia is a waste product naturally produced in the body. It primarily comes from the digestion of protein by bacteria in the intestines. If not processed by the liver and cleared from the body appropriately, excess ammonia can accumulate in the blood and pass from the blood into the brain, where it is toxic.

an enzyme that helps regulate blood pressure.

Associated with inappropriate blood clotting

contributes to the diagnosis of APS

contributes to the diagnosis of APS

Blood's main acid-base buffer; measured on CMP as CO2.

A liver protein that rises when there is inflammation.

assess the risk of cardiovascular and peripheral vascular disease

useful in judging the extent of carbon monoxide toxicity and in considering the effect of smoking

Carboxyhemoglobin is a form of hemoglobin that develops when carbon monoxide (CO) binds to red blood cells. Carbon monoxide has a much stronger affinity for hemoglobin than oxygen does—over 200 times stronger—so even modest exposure can reduce the body’s ability to carry oxygen. This test measures the percentage of total hemoglobin bound to carbon monoxide and is used to evaluate oxygen-carrying capacity, detect carbon monoxide exposure, and assess smoking status or environmental/occupational risks. A carboxyhemoglobin level above 2% but below 5% is typically seen in individuals who are exposed to low levels of carbon monoxide, most commonly light or moderate smokers or people who are regularly around secondhand smoke or mild environmental CO sources. While this range is above the normal nonsmoker reference (<2%), it is not generally considered dangerous on its own. However, it does indicate that the body’s oxygen-carrying capacity is slightly reduced, which may contribute to symptoms like mild headaches, fatigue, or decreased exercise tolerance in sensitive individuals. For those who do not smoke, a result in this range may prompt evaluation for hidden carbon monoxide exposure, such as from poor indoor ventilation, gas appliances, garage exhaust, or occupational settings. Reducing environmental CO exposure, improving ventilation, and avoiding smoke can help bring levels back into the nonsmoker range.

Understanding Clauss Fibrinogen: A Comprehensive Guide to Blood Clotting and Health What is Clauss Fibrinogen? Clauss fibrinogen is a specialized blood test that measures fibrinogen activity using advanced laboratory techniques. Unlike standard protein measurements, this method evaluates both the quantity and functionality of fibrinogen, a key blood-clotting protein. How the Clauss Test Works Measures fibrinogen's ability to form clots. Determines clotting protein concentration. Offers more accurate results compared to traditional assays. Reduces interference from other blood components. The Role of Fibrinogen in Your Body Fibrinogen, produced by the liver, is essential for various physiological functions beyond clotting. It is a critical marker for understanding overall health. Key Functions of Fibrinogen Forms the primary structure of blood clots. Acts as a marker for inflammation. Aids in wound healing and tissue repair. Supports immune responses during infections or injuries. Normal Clauss Fibrinogen Levels Understanding the reference ranges for Clauss fibrinogen levels is essential for interpreting test results. Standard Reference Ranges Healthy Adults: 2.0–4.0 g/L Pregnancy: Levels naturally increase, often up to 6.0 g/L. Note: Ranges may vary between laboratories. What Do Abnormal Clauss Fibrinogen Levels Mean? Low Fibrinogen Levels (< 2.0 g/L) Associated Risks: Increased bleeding risk. Potential Causes: Liver dysfunction. Disseminated intravascular coagulation (DIC). Genetic fibrinogen disorders. High Fibrinogen Levels (> 4.0 g/L) Associated Risks: Increased blood clot formation. Potential Causes: Chronic inflammation. Cardiovascular disease. Autoimmune conditions. Causes of Fibrinogen Level Variations Factors That Increase Fibrinogen Chronic inflammatory conditions. Cardiovascular diseases. Smoking and obesity. Chronic stress or anxiety. Pregnancy or certain medications. Factors That Decrease Fibrinogen Severe liver disease. Extensive surgery or significant blood loss. Genetic fibrinogen disorders. Why Clauss Fibrinogen Matters The Clauss fibrinogen test provides valuable insights into your health. Key Clinical Significance Evaluates the health of your coagulation system. Reveals potential inflammatory or autoimmune processes. Assesses cardiovascular risk. Supports overall health evaluation. Managing Abnormal Fibrinogen Levels Proactive Health Management Medical Monitoring: Regular testing to track changes. Lifestyle Changes: Anti-inflammatory diet, exercise, and stress reduction. Targeted Treatments: Address underlying health conditions with medical interventions. Recommended Lifestyle Modifications Follow an anti-inflammatory diet rich in omega-3s, fruits, and vegetables. Engage in regular physical activity. Manage stress with mindfulness or relaxation techniques. Maintain a healthy weight and avoid smoking. When to See a Doctor About Fibrinogen Levels Testing Scenarios to Consider Unexplained bleeding or easy bruising. Persistent signs of inflammation, such as swelling or fatigue. Family history of clotting disorders. Concerns about cardiovascular health. Pre-surgical evaluations. Key Takeaways Clauss fibrinogen testing is a vital tool for understanding your blood's clotting ability and identifying potential health risks. By detecting abnormalities early, you can take proactive steps to prevent complications and maintain overall well-being. Steps for Optimal Health Schedule regular blood tests to monitor fibrinogen levels. Consult your healthcare provider to interpret results in context. Develop a personalized health plan to address abnormal levels. Note: Always consult a qualified healthcare provider to interpret test results and create a tailored health strategy.

This test evaluates copper stores and accumulation.

CRP/ESR Ratio – What Your Lab Results Mean CRP/ESR Ratio is a calculated value that compares levels of C-reactive protein (CRP) to the erythrocyte sedimentation rate (ESR)—two common markers used to detect inflammation in the body. This ratio can provide deeper insight into the type and intensity of inflammation, helping to distinguish between different causes of inflammatory responses. What Do CRP and ESR Measure? C-reactive protein (CRP) is a protein produced by the liver in response to acute inflammation. Its levels rise quickly within hours of tissue injury or infection. Erythrocyte Sedimentation Rate (ESR) measures how quickly red blood cells settle at the bottom of a test tube in one hour. It increases more slowly and reflects more chronic or long-term inflammation. Why the CRP/ESR Ratio Matters The CRP/ESR Ratio provides a more nuanced picture of inflammatory activity. Here's how to interpret it: High CRP/ESR Ratio: Suggests a more acute or bacterial infection-type inflammation (e.g., pneumonia, sepsis). CRP tends to rise sharply in such conditions, while ESR increases more slowly. Low CRP/ESR Ratio: May indicate chronic inflammation, autoimmune conditions (e.g., lupus or rheumatoid arthritis), or conditions where ESR is elevated but CRP remains relatively low. This ratio is especially useful in rheumatology and infectious disease to help distinguish between types of inflammation or to monitor disease progression and response to treatment. What Is a Normal CRP/ESR Ratio? There’s no universal reference range, but a ratio of: >2 may point toward acute inflammation or bacterial infection <1 may suggest chronic or autoimmune inflammation It's important to interpret this ratio in context with symptoms, clinical history, and other lab findings. Always consult your healthcare provider for a comprehensive evaluation. Key Takeaway The CRP/ESR Ratio is a valuable tool that helps differentiate between acute and chronic inflammation. It adds depth to your lab results and may guide more precise diagnosis and treatment—especially when inflammation is suspected.

Cryoglobulin, Qualitative with Reflex to Quantitative and Immunofixation – Labcorp Test 001594 Labcorp's Cryoglobulin, Qualitative with Reflex to Quantitative and Immunofixation is a diagnostic assay designed to detect and characterize cryoglobulins in serum. Cryoglobulins are abnormal proteins that precipitate from blood at temperatures below 37°C and dissolve upon rewarming. Their presence can lead to various clinical manifestations, including vasculitis, purpura, and neuropathy. Clinical Utility This test is particularly useful in evaluating patients with suspected cryoglobulinemia associated with: Hematologic disorders such as Waldenström macroglobulinemia, multiple myeloma, and chronic lymphocytic leukemia. Autoimmune diseases including systemic lupus erythematosus (SLE) and rheumatoid arthritis. Chronic infections, notably hepatitis C. The test aids in identifying the underlying cause of symptoms like cold-induced skin lesions, joint pain, and peripheral neuropathy. Interpretation A negative result indicates no cryoglobulins detected. Positive results are reported as percentages and further analyzed to determine the cryoglobulin type. The presence of cryoglobulins, especially in the context of the aforementioned conditions, can guide clinicians in diagnosis and management strategies. For more detailed information or to order the test, please visit Labcorp's official page.

a protein fragment that's made when a blood clot dissolves in your body.

a protein fragment that's made when a blood clot dissolves in your body.

can help diagnose porphyrias, lead or mercury poisoning

An aid in distinguishing between primary and secondary polycythemia

measuring oxidative stress in the body

helps the blood clot.

Venous thromboembolism is a complex condition that can be caused by a combination of genetic factors, lifestyle choices, and specific situations. One key genetic risk factor is the presence of a specific change in the F5 gene, known as Factor V Leiden (c.1601G>A or p. Arg534Gln variant). People who carry one copy of this variant are 6 to 8 times more likely to develop venous thromboembolism, while those with two copies (one from each parent) face an approximately 80 times higher risk. The risk increases even further for individuals who carry both the Factor V Leiden variant and another variant called c.*97G>A in the F2 gene, making them about 20 times more susceptible. Certain combinations of genetic factors, including both mentioned variants, could further elevate this risk. Other risk factors that can contribute to the development of venous thromboembolism include low levels of certain proteins (protein C, protein S, or antithrombin III), being older, male, having a personal or family history of blood clots, smoking, undergoing surgery, being immobile for long periods, having cancer, or receiving treatments like tamoxifen, raloxifene, oral contraceptives, hormone replacement therapy, and being pregnant. To manage the risk of blood clots, it's essential to follow established medical guidelines tailored to each person's situation. Genetic counseling can also provide valuable information on the implications of test results and advise on testing for family members. The Factor V Leiden variant mentioned is the main focus of testing, which has a diagnostic accuracy greater than 99%. However, it's important to interpret these results in the context of the individual's overall health and other risk factors. While molecular-based tests are very reliable, they are not perfect and can sometimes give false results due to various factors like other genetic variations, blood transfusions, bone marrow transplants, sample mix-ups, or inaccuracies in family history documentation.

one of the proteins in the body that helps the blood clot.

Clotting protein test; high raises clot risk, low may mean hemophilia.

involved in blood clotting

Blood Health

Blood Health

Blood Clotting

Essential for proper blood clot formation

to help diagnose a G6PD deficiency

Glucose 6-Phosphate Dehydrogenase, often abbreviated as G6PD (or G-6-PD), plays a critical role in the body's cellular function. This enzyme is vital for the health of all cells, but it's particularly crucial for red blood cells. G6PD helps cells manage oxidative stress. Oxidative stress occurs when there's an imbalance between the production of harmful free radicals (unstable molecules that can damage cells) and the body's ability to counteract their harmful effects through neutralization with antioxidants. G6PD aids in the production of NADPH, a molecule that plays a key role in the antioxidant defense system of cells. Specifically, NADPH helps maintain the supply of glutathione, a powerful antioxidant that protects red blood cells from damage. The importance of G6PD comes into the spotlight when we consider its role in maintaining the integrity and functionality of red blood cells. These cells are responsible for transporting oxygen from the lungs to the rest of the body and returning carbon dioxide back to the lungs for exhalation. Because red blood cells are continuously exposed to oxygen, they are particularly susceptible to oxidative damage. G6PD ensures that red blood cells can protect themselves against such damage and thus, maintain their crucial function in oxygen transportation. However, when there's a deficiency in G6PD, red blood cells are more vulnerable to oxidative stress, leading to a condition known as hemolytic anemia. In hemolytic anemia, red blood cells are destroyed faster than they can be made, resulting in fatigue, jaundice (a yellowing of the skin and eyes), and other symptoms due to the lack of adequate oxygen delivery to the body's tissues. This condition can be triggered by various factors, including certain foods, infections, and medications that increase oxidative stress within red blood cells. A G6PD test, specifically a quantitative test, measures the exact amount of the enzyme present in the blood. This test is crucial for diagnosing G6PD deficiency. Knowing the precise levels of G6PD helps healthcare providers manage and advise patients with the deficiency on how to avoid triggers that may lead to hemolytic anemia. It's particularly important in regions where G6PD deficiency is common or for individuals of certain ethnic backgrounds that have a higher prevalence of this condition. Understanding G6PD and its significance requires a look at both the cellular level, where it helps protect cells from oxidative damage, and the broader impacts, such as its role in preventing hemolytic anemia. Through the quantitative measurement of G6PD, healthcare providers can better diagnose, manage, and provide guidance to those affected by G6PD deficiency, improving their quality of life and preventing potential complications.

Glutathione (GSH) is a tripeptide (λ-glutamyl-cysteinylglycine) synthesized by most cells, serving as a critical marker of cellular health and resilience against toxic stress. In erythrocytes, GSH levels are a sensitive indicator of the body's intracellular GSH status and overall cellular well-being. It is the most abundant non-protein thiol in mammalian cells, playing key roles in various biological processes, such as detoxifying harmful compounds (xenobiotics), neutralizing reactive oxygen species, regulating cellular redox balance, and maintaining the oxidative state of vital protein sulfhydryl groups. Additionally, GSH supports immune function. Intracellular GSH concentrations are significantly higher than plasma levels, with plasma GSH largely derived from the liver. The active form, reduced GSH (rGSH), is maintained at a ratio of approximately 9:1 with its oxidized counterpart (GSSH) in healthy cells. However, once a blood sample is collected, erythrocyte rGSH is highly prone to oxidation, rapidly diminishing the rGSH ratio. Due to the impracticality of preventing ex vivo oxidation and the challenges of directly measuring rGSH in clinical settings, it is more feasible to assess total erythrocyte GSH as an indicator of overall GSH status. Research suggests that an unfavorable rGSHratio is closely associated with abnormally low total cellular GSH levels.

Hemolytic Anemia test

Hemoglobin A, featured prominently on the Thalassemia and Hemoglobinopathy Comprehensive (COMP) panel, is a critical component in diagnosing and managing blood disorders. This panel is an essential tool used to detect various forms of thalassemia and hemoglobinopathies, conditions characterized by abnormal hemoglobin production. Hemoglobin A, the most common form of hemoglobin in adults, is composed of two alpha and two beta globin chains. The Thalassemia and Hemoglobinopathy COMP panel measures the percentage of Hemoglobin A in the blood, which is crucial for diagnosing conditions like beta-thalassemia or sickle cell disease. In normal individuals, Hemoglobin A constitutes the majority of hemoglobin. However, in disorders like beta-thalassemia, there is a reduced production of beta globin chains, leading to a lower percentage of Hemoglobin A. Similarly, in sickle cell disease, a mutation in the beta globin gene results in abnormal hemoglobin, known as Hemoglobin S, reducing the proportion of Hemoglobin A. The accurate quantification of Hemoglobin A through this panel is instrumental in differentiating between various hemoglobinopathies and thalassemia syndromes, thereby guiding appropriate treatment strategies.

Hemoglobin F, an integral component analyzed in the Thalassemia and Hemoglobinopathy Comprehensive (COMP) panel, holds significant diagnostic value in the field of hematology. This panel is extensively utilized to detect and manage various blood disorders, specifically thalassemia and hemoglobinopathies, which involve abnormal hemoglobin production or structure. Hemoglobin F, or fetal hemoglobin, normally present in high levels in fetuses and newborns, is comprised of two alpha and two gamma globin chains. Its proportion in adult blood is typically low but can be elevated in certain hematological conditions. The Thalassemia and Hemoglobinopathy COMP panel assesses the percentage of Hemoglobin F in the blood, which is crucial for diagnosing disorders like beta-thalassemia or Delta-Beta thalassemia. In these conditions, there is a disruption in beta-chain production, leading to a compensatory increase in gamma chains, thus elevating Hemoglobin F levels. Additionally, Hemoglobin F levels are also analyzed to diagnose and manage sickle cell disease, where increased Hemoglobin F can ameliorate disease symptoms. Precise measurement of Hemoglobin F through this panel aids in differentiating between various types of thalassemia and hemoglobinopathies, guiding clinicians in devising effective treatment and management strategies. The inclusion of Hemoglobin F in this comprehensive panel highlights the advancements in medical diagnostics, emphasizing its crucial role in enhancing patient care through the early detection and efficient management of genetic blood disorders.

IRF measures young RBCs, indicating bone marrow activity and aiding anemia diagnosis.

can be a useful marker of thrombopoietic activity.

Shows the youngest share of reticulocytes and early production changes.

The human body requires iron to perform many vital physiological functions

Blood cell production

When illness or injury damages your cells, LDH may be released into the bloodstream.

Large white blood cells, usually activated lymphocytes responding to infection.

Inflammation/viruses test

condition characterized by the presence of abnormally large red blood cells

Mineral and electrolyte

The nucleated red blood cell count, reported as a percentage.

Immature red blood cells with a nucleus; absent in healthy adults.

Oxidized Phospholipids on apoB (OxPL-apoB)

What is PBG Deaminase? PBG Deaminase (also called porphobilinogen deaminase, uroporphyrinogen I synthase, or hydroxymethylbilane synthase) is a key enzyme in the heme biosynthesis pathway — the process by which your body makes heme, a vital component of hemoglobin, myoglobin, and other important proteins. Heme is essential for transporting oxygen in the blood and for many cellular processes, including energy production and detoxification. PBG Deaminase is the third enzyme in this pathway and plays a critical role in converting porphobilinogen (PBG) into hydroxymethylbilane, which eventually becomes heme. Why is PBG Deaminase Measured in Whole Blood? The PBG Deaminase, WB test measures the activity of the PBG Deaminase enzyme in red blood cells. Measuring enzyme activity in whole blood helps detect certain inherited disorders of heme metabolism, especially acute intermittent porphyria (AIP). Clinical Relevance: Acute Intermittent Porphyria (AIP) AIP is a rare genetic metabolic disorder caused by a partial deficiency of PBG Deaminase. People with AIP cannot properly break down porphyrin precursors, leading to a buildup of toxic substances like ALA (aminolevulinic acid) and PBG in the body. This can cause serious and sometimes life-threatening symptoms, particularly affecting the nervous system. Symptoms of AIP May Include: Sudden, severe abdominal pain (without clear cause) Muscle weakness or paralysis Anxiety, confusion, or hallucinations Seizures Rapid heart rate or high blood pressure Dark-colored urine (due to excess porphyrins) Attacks are often triggered by medications, fasting, stress, infection, or hormonal changes. Identifying low PBG Deaminase activity helps confirm a diagnosis, especially when paired with elevated levels of ALA and PBG in the urine during an attack. What Does an Abnormal Result Mean? Low PBG Deaminase Activity Strongly suggests AIP, particularly when symptoms and other porphyrin-related tests align. May also indicate a silent genetic carrier (someone with a mutation who may never have symptoms but can pass it on to offspring). Important for family screening—AIP is inherited in an autosomal dominant pattern, meaning only one copy of the gene mutation is needed to be at risk. Normal or High Activity Makes AIP unlikely, especially if other tests (urinary ALA, PBG) are also normal. Other types of porphyria or conditions with similar symptoms may need to be ruled out. Who Should Be Tested? Testing PBG Deaminase activity is typically recommended for individuals who: Have symptoms suggestive of AIP Have family members with AIP Have had positive urine porphyrin screening tests Are undergoing differential diagnosis for unexplained abdominal pain and neurological symptoms Important Notes About the Test Sample type: Whole blood, typically collected in EDTA tubes. The enzyme is heat-sensitive, so the sample must be kept cold and processed quickly to avoid degradation. Results should be interpreted in the context of clinical symptoms, family history, and other porphyrin-related tests. Follow-Up and Management If PBG Deaminase activity is low and AIP is diagnosed: Your healthcare provider may recommend genetic testing to identify specific mutations. You may need to avoid triggering medications, manage stress, and maintain a balanced diet to prevent acute attacks. In some cases, heme arginate or glucose infusions are used to treat attacks. Summary PBG Deaminase, WB is a specialized enzyme test used primarily to diagnose acute intermittent porphyria (AIP) — a rare but serious disorder of heme synthesis. Low enzyme activity confirms the presence of a genetic defect affecting heme metabolism, often requiring lifestyle adjustments and medical supervision to prevent dangerous metabolic crises.

Plasminogen Activator Inhibitor 1 (PAI-1) Activity is a marker measured in a blood test that helps understand how easily your blood clots or dissolves clots, playing a crucial role in your body's ability to manage bleeding and healing. PAI-1 is a protein produced by various cells in your body, including those lining your blood vessels and fat cells. It acts as a natural brake in the clot-dissolving process; when its levels are within a normal range, it helps maintain a delicate balance between forming clots to stop bleeding and breaking them down to keep blood vessels clear and prevent blockages. However, if PAI-1 activity is too high, it can tip this balance, making it harder for the body to dissolve blood clots. This can increase the risk of developing conditions like deep vein thrombosis (a blood clot in a deep vein, usually in the legs), heart attacks, or strokes, especially if other risk factors are present. On the other hand, very low levels of PAI-1 can lead to excessive bleeding. Testing PAI-1 activity as part of a panel from Labcorp allows healthcare providers to evaluate your risk of clot-related conditions and bleeding disorders, contributing to a comprehensive assessment of your vascular health. Understanding your PAI-1 levels can help your healthcare team make informed decisions about prevention strategies, lifestyle adjustments, or treatments necessary to manage your risk of clotting or bleeding problems effectively.

The Platelet Antibodies, Indirect (IgG, IgM, IgA) panel, featuring the Platelet Ab, Indirect (IgA) test, is a significant diagnostic asset in the realms of hematology and immunology, particularly for assessing conditions like thrombocytopenia (low platelet count) and platelet dysfunction. The Platelet Ab, Indirect (IgA) component specifically measures the presence of immunoglobulin A (IgA) antibodies that target platelets. These antibodies are crucial in diagnosing autoimmune conditions where the immune system mistakenly attacks and destroys its own platelets, leading to thrombocytopenia. The presence of IgA platelet antibodies can indicate Immune Thrombocytopenia (ITP), where these antibodies mark platelets for destruction. Additionally, this test is valuable in identifying drug-induced thrombocytopenia, where certain medications stimulate the production of platelet-specific antibodies, and in rare conditions like post-transfusion purpura, following a blood transfusion. The Platelet Ab, Indirect (IgA) test in this comprehensive panel is pivotal for accurate diagnosis, ongoing monitoring, and effective management of these disorders. Its ability to sensitively detect IgA antibodies against platelets is key in guiding treatment strategies, which might include immunosuppressive therapy or specific platelet transfusion management.

The Platelet Antibodies, Indirect (IgG, IgM, IgA) panel, featuring the Platelet Ab, Indirect (IgG) test, is a critical diagnostic tool in the field of hematology and immunology, particularly in the evaluation of thrombocytopenia (low platelet count) and platelet dysfunction disorders. The Platelet Ab, Indirect (IgG) test specifically measures the presence of immunoglobulin G (IgG) antibodies that are directed against platelets. These antibodies play a significant role in various autoimmune conditions, where the body’s immune system mistakenly targets and destroys its own platelets, leading to a decreased platelet count. Conditions such as Immune Thrombocytopenia (ITP), in which IgG antibodies bind to platelets and enhance their destruction in the spleen, are commonly diagnosed with the help of this test. Additionally, this test is instrumental in evaluating patients for possible drug-induced thrombocytopenia, where certain medications stimulate the production of platelet-directed antibodies, and in post-transfusion purpura, a rare but serious condition following blood transfusion. The Platelet Ab, Indirect (IgG) test in the comprehensive panel offers vital information for diagnosing, monitoring, and managing these complex conditions. Its accurate and sensitive detection of IgG antibodies against platelets is crucial in guiding treatment strategies, including immunosuppressive therapy or platelet transfusion management.

The Platelet Antibodies, Indirect (IgG, IgM, IgA) panel, which includes the Platelet Ab, Indirect (IgM) test, is a crucial diagnostic tool in the realm of hematology and immunology, specifically for evaluating thrombocytopenia and platelet dysfunction disorders. The Platelet Ab, Indirect (IgM) test focuses on detecting the presence of immunoglobulin M (IgM) antibodies targeting platelets. These IgM antibodies are important in identifying autoimmune conditions and other disorders where the body's immune system erroneously attacks and destroys its own platelets, leading to a reduced platelet count. The presence of IgM platelet antibodies can be indicative of Immune Thrombocytopenia (ITP), a condition where these antibodies bind to platelets, marking them for destruction. This test is also valuable in diagnosing drug-induced thrombocytopenia, where certain medications trigger the production of platelet-specific antibodies, and in conditions like post-transfusion purpura, a rare complication following blood transfusion. The Platelet Ab, Indirect (IgM) test in this panel is instrumental for the accurate diagnosis, monitoring, and management of these disorders. Its ability to detect IgM antibodies against platelets is key to guiding appropriate treatment strategies, such as immunosuppressive therapy or tailored platelet transfusion regimens.

Platelet volume percentage in blood

Young red cells on a smear, graded by eye.

To confirm a diagnosis of acute intermittent porphyria

porphyrias are a group of inherited disorders

The PTT-LA Ratio is an essential part of lupus anticoagulant (LA) testing. It is calculated using a modified partial thromboplastin time (PTT) test that employs a low-phospholipid reagent, making it highly sensitive to the presence of lupus anticoagulant. A normal PTT-LA ratio is typically ≤1.20. An elevated PTT-LA ratio may suggest the presence of lupus anticoagulant—an antibody that paradoxically increases the risk of blood clots, even though it prolongs clotting times in laboratory tests. This test is commonly performed alongside other assays, such as the dilute Russell viper venom time (dRVVT), as part of a comprehensive lupus anticoagulant panel. However, results can be influenced by factors such as anticoagulant medications, liver disease, or other underlying conditions. Therefore, the patient's clinical context must always be taken into account for accurate interpretation.

Lupus anticoagulant screen

important role in assessing iron status and erythropoiesis

To help evaluate the bone marrow's ability to produce red blood cells (RBCs).

Ret-He measures hemoglobin in reticulocytes, crucial for diagnosing and managing anemia.

red blood cells that are still developing

A sickle cell screen, also known as a sickle cell test or sickle cell screening, is a medical test used to determine whether an individual carries a gene mutation associated with sickle cell disease (SCD). Sickle cell disease is a genetic disorder that affects the shape of red blood cells, causing them to become rigid and assume a characteristic "sickle" shape. These misshapen red blood cells can lead to various health problems, including pain, anemia, and organ damage. The sickle cell screen typically involves a blood test to detect the presence of abnormal hemoglobin, the protein responsible for carrying oxygen in red blood cells. The two most common types of abnormal hemoglobin associated with sickle cell disease are: Hemoglobin S (HbS): This is the abnormal hemoglobin found in individuals with sickle cell disease. People who inherit one copy of the HbS gene and one normal hemoglobin gene (HbA) are considered carriers or have sickle cell trait. They may not have symptoms of the disease but can pass the gene on to their offspring. Hemoglobin C (HbC): Hemoglobin C is another abnormal hemoglobin variant that can be detected through screening. Individuals with one copy of the HbC gene and one normal hemoglobin gene (HbA) may have a condition called hemoglobin C trait. The sickle cell screen is often performed as part of newborn screening programs, especially in regions where sickle cell disease is more common, such as parts of Africa, the Mediterranean, the Middle East, and certain areas in the Americas. Early detection through screening allows for timely intervention and management to prevent or mitigate the complications associated with sickle cell disease. In addition to newborn screening, sickle cell screening may also be recommended for individuals who are planning to have children, as knowing their carrier status can help assess the risk of passing the disease to their offspring. It can also be offered to individuals from populations with a higher prevalence of sickle cell disease. It's important to note that a sickle cell screen does not diagnose sickle cell disease itself but rather identifies carriers of the gene mutations associated with the condition. Further tests, such as hemoglobin electrophoresis or genetic testing, may be required to confirm the diagnosis of sickle cell disease or trait in individuals who screen positive.

Functional iron availability marker

Stomatocytes are a unique type of red blood cells (RBCs) characterized by their distinct mouth-like shape, playing a significant role in the field of hematology and medical diagnostics. These cells, identifiable under a microscope, present with a central, slit-like area devoid of hemoglobin, giving them their characteristic appearance. The presence of stomatocytes in a blood smear is a key indicator in diagnosing various hematological disorders, including hereditary stomatocytosis, a rare condition affecting the membrane of red blood cells. Additionally, increased levels of stomatocytes can be associated with alcoholism, liver disease, and certain medications. The detection of these abnormal cells is critical in understanding the underlying causes of anemia and other blood-related issues. Healthcare professionals rely on identifying stomatocytes to aid in accurate diagnosis and effective treatment planning, highlighting their importance in comprehensive blood analysis. Their unique morphology and clinical relevance make stomatocytes a vital component in advanced hematology studies, contributing significantly to patient care and medical research.

Blood Health

Transferrin iron-carrying capacity reflecting iron stores and liver function.

The main iron-transport protein in blood, produced by the liver.

The Transferrin Receptor, a critical protein in iron metabolism, plays a pivotal role in diagnosing and managing iron-related disorders, making it an essential biomarker in modern medical diagnostics. This receptor, found on the surface of most cells, particularly erythroblasts, binds to transferrin, the primary iron transport protein in the blood, facilitating the uptake of iron into cells. Measuring the levels of soluble transferrin receptor (sTfR) in the blood provides crucial insights into the body's iron status, especially in distinguishing between iron deficiency anemia and anemia of chronic disease. Elevated sTfR levels are typically indicative of iron deficiency, as the body increases the production of transferrin receptors to enhance iron uptake in conditions of iron scarcity. In contrast, low levels of sTfR are often seen in conditions where there is sufficient or excess iron. The transferrin receptor is particularly valuable in scenarios where traditional markers of iron status, like ferritin, may be unreliable, such as in patients with inflammation or chronic illness. Its measurement is increasingly used in conjunction with other iron parameters to give a comprehensive picture of iron homeostasis, aiding in the precise diagnosis and effective management of anemia and other iron-related disorders. The importance of the transferrin receptor in clinical practice underscores its value in advancing personalized healthcare and improving patient outcomes in hematological and iron metabolism conditions.

Percentage of transferrin bound to iron; elevated may indicate iron overload.

Unsaturated Iron-Binding Capacity

involved in a few stages of blood clotting

VWF GPIbM Activity (Von Willebrand Factor Glycoprotein Ib-Mutant Activity) What Is VWF GPIbM Activity? VWF GPIbM Activity is a specialized test that measures the functional activity of von Willebrand factor (VWF) — a protein essential for normal blood clotting. This assay assesses how well VWF can bind to platelets, a key step in the formation of a blood clot to stop bleeding. The test uses a mutant form of platelet receptor GPIbα (glycoprotein Ib alpha) to detect VWF activity, which makes it more stable, sensitive, and specific than older tests like the ristocetin cofactor assay (VWF:RCo). VWF GPIbM Activity is used primarily in the diagnosis and classification of von Willebrand disease (VWD), the most common inherited bleeding disorder. Understanding VWF and GPIbα Von Willebrand factor (VWF) is a large multimeric protein made by endothelial cells and megakaryocytes. It has two main jobs: Binding to collagen at sites of blood vessel injury Binding to platelets via the GPIbα receptor, helping them stick together to form a clot The interaction between VWF and GPIbα is crucial for primary hemostasis (the first step in stopping bleeding). When VWF can’t bind properly to platelets, bleeding may become prolonged or excessive. What Does the GPIbM Activity Test Measure? This test evaluates the ability of VWF in your blood to bind to the GPIbα receptor. The “M” in GPIbM stands for mutant, indicating that the test uses a recombinant (lab-engineered) form of the GPIb receptor that binds VWF without the need for ristocetin, an antibiotic previously used in older assays. Compared to the traditional VWF:RCo test, the VWF GPIbM assay offers: Better precision and reproducibility Less sensitivity to pre-analytical variables No interference from ristocetin cofactor variability More accurate diagnosis of von Willebrand disease, especially type 2 variants Why Is This Test Important? VWF GPIbM Activity is used to: Diagnose von Willebrand disease (VWD) Differentiate between types of VWD (e.g., type 1, type 2A, 2B, 2M, 2N) Assess functional activity of VWF in suspected bleeding disorders Monitor response to VWF replacement therapy in certain patients Evaluate unexplained prolonged bleeding time, easy bruising, or excessive bleeding after surgery or injury Reference Ranges and Interpretation Typical reference values for VWF GPIbM Activity are: Normal range: ~50% to 150% (or 0.50–1.50 IU/mL), but exact cutoffs depend on the lab Always interpret results alongside VWF antigen, VWF multimer analysis, Factor VIII, and platelet function tests. What Do Abnormal VWF GPIbM Activity Results Mean? Low VWF GPIbM Activity Low activity suggests reduced or impaired function of von Willebrand factor, even if the amount of VWF is normal. This can indicate: 1. Type 1 VWD (Partial Quantitative Deficiency) Both VWF antigen and activity are reduced proportionally Mild to moderate bleeding tendency 2. Type 2 VWD (Qualitative Defects) VWF antigen may be normal, but activity is significantly reduced Subtypes: Type 2A: Loss of high-molecular-weight multimers (essential for function) Type 2B: Increased affinity for platelets (may cause thrombocytopenia) Type 2M: Decreased function despite normal multimers These types can lead to moderate or severe bleeding symptoms 3. Acquired von Willebrand Syndrome Caused by autoimmune disorders, heart valve disease, certain cancers, or hypothyroidism 4. Severe VWD (Type 3) Undetectable or nearly absent VWF activity and antigen Causes severe bleeding and usually diagnosed early in life High VWF GPIbM Activity Elevated VWF activity is uncommon but may be seen in: Inflammation or infection Pregnancy Stress or trauma Diabetes Cardiovascular disease Liver disease (increased synthesis of clotting proteins) Post-surgical or acute-phase states High levels typically do not indicate disease, but in rare cases, very high VWF activity may contribute to thrombosis (excessive clotting), particularly in combination with other risk factors. Symptoms Associated With Low VWF Activity If your VWF GPIbM Activity is low, you may experience symptoms such as: Easy bruising Frequent nosebleeds Heavy or prolonged menstrual bleeding Bleeding gums Excessive bleeding after dental work, surgery, or trauma Prolonged bleeding time on minor cuts Who Should Get This Test? You may be a candidate for VWF GPIbM testing if you: Have unexplained bleeding symptoms Have a family history of bleeding disorders Have abnormal coagulation studies (e.g., prolonged aPTT or bleeding time) Are being evaluated for von Willebrand disease Need confirmation of a VWD subtype before treatment decisions Are being monitored during VWF therapy or DDAVP (desmopressin) treatment How the Test Is Performed Sample type: Blood (plasma) No special preparation is typically required May be ordered along with: VWF Antigen (VWF:Ag) Factor VIII activity VWF Collagen Binding (VWF:CB) VWF Multimer Analysis Platelet count and function tests Summary VWF GPIbM Activity is a modern, sensitive test that measures how well your von Willebrand factor binds to platelets — a critical step in normal blood clotting. It is essential in diagnosing von Willebrand disease, especially in detecting functional defects that may be missed by standard antigen tests. Whether you're being evaluated for a bleeding disorder or are already receiving treatment, this test provides a more accurate view of VWF activity and its impact on clotting function.

Understanding Whole Blood Lactate: What Your Lab Results Mean Whole Blood Lactate is a biomarker often measured to assess metabolic health and tissue oxygenation. It reflects the amount of lactate, a byproduct of glucose metabolism, circulating in your bloodstream. This test is particularly relevant when evaluating conditions such as lactic acidosis, sepsis, or other metabolic or circulatory disorders. What Is Whole Blood Lactate? Lactate is produced when your body breaks down glucose for energy in low-oxygen environments, such as during intense exercise or when oxygen delivery to tissues is impaired. While some lactate is normal, elevated levels can indicate an underlying issue with oxygen utilization or metabolic function. Normal and Abnormal Levels Normal Range: Typically, lactate levels in whole blood are between 0.5–2.5 mmol/L, though this may vary slightly depending on the laboratory and whether arterial or venous blood is tested. Elevated Levels (Hyperlactatemia): Higher levels may suggest various conditions or situations: Sepsis or severe infections Cardiac or respiratory failure Shock Certain metabolic disorders Intense physical activity Medication effects Common Causes of Elevated Lactate Sepsis or Infection: Severe infections can impair oxygen delivery, leading to elevated lactate. Shock or Hypoxia: Conditions reducing blood flow or oxygen to tissues. Liver Dysfunction: The liver plays a key role in breaking down lactate, and impaired function can cause accumulation. Medications or Toxins: Certain drugs, like metformin, or toxins like alcohol, may contribute to increased levels. Intense Exercise: Strenuous physical activity can temporarily increase lactate levels. Why Is It Important? Monitoring lactate levels helps healthcare providers gauge the severity of acute conditions like sepsis or evaluate how well treatments are working. It's also critical in managing chronic conditions affecting metabolism or oxygen delivery. In sports medicine, lactate testing is used to assess athletic performance and design training programs. How Is the Test Performed? Lactate can be measured in both blood and cerebrospinal fluid. For blood tests: A small blood sample is taken, usually from a vein or artery. Point-of-care devices allow for rapid assessment in emergency settings. Results are typically available within minutes to a few hours, depending on the method used. Hyperlactatemia vs. Lactic Acidosis Hyperlactatemia: Elevated lactate levels in the blood (typically >2.5 mmol/L). Lactic Acidosis: A more severe condition where high lactate levels (usually >4 mmol/L) are accompanied by a decrease in blood pH, indicating metabolic acidosis. What to Do If Your Levels Are Abnormal If your Whole Blood Lactate is elevated, follow up with your healthcare provider for further evaluation. They may recommend additional tests to determine the cause and guide treatment. Lifestyle changes, such as improved hydration, regular exercise, or managing chronic conditions, can also help maintain normal lactate levels. Conclusion Whole Blood Lactate is a valuable marker that provides insights into your metabolic health and oxygen delivery. Understanding its implications can empower you to take proactive steps in managing your health. If you notice abnormal levels, consult your healthcare provider to explore the underlying causes and appropriate interventions.